Back to search

Peptide record

TPDB11398

Odorranain-C1 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity standard
33 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11398
Odorranain-C1
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 Antifungipept CAFPdb ToxinPred 3.0
standard
No
A 33-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
GVLGAVKDLLIGAGKSAAQSVLKTLSCKLSNDC
Physicochemical Analysis
C140H247N39O45S2
REHMFPWY
L
3260.86
9.05
4
2
14
+2
3.50
0.515
121.21
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
125
3.83
9
Residue Composition
number
4
A
0
R
1
N
2
D
2
C
0
E
1
Q
4
G
0
H
1
I
6
L
4
K
0
M
0
F
0
P
4
S
1
T
0
W
0
Y
3
V
Amino Acid Distribution
A: 4 R: 0 N: 1 D: 2 C: 2 E: 0 Q: 1 G: 4 H: 0 I: 1 L: 6 K: 4 M: 0 F: 0 P: 0 S: 4 T: 1 W: 0 Y: 0 V: 3
Chemical Descriptors
33
C140H247N39O45S2
3260.86
9.05
+2
3.50
0.515
Free
L
Linear
Free
Anticancer
Odorrana grahami
Evidence Records 29 records
Evidence 1 Activity

Activity

MIC
Antibacterial
8.2-12 µg/mL

Target

Escherichia coli ATCC 35150 or ATCC 10305

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
active against E. coli ATCC 35150 or ATCC 10305 (MIC 8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogen
Evidence 2 Activity

Activity

MIC
Antibacterial
4.1-10 µg/mL

Target

Staphylococcus aureus ATCC 25923

Source & Reference

dbAMP DRAMP

Other

active against E. coli ATCC 35150 or ATCC 10305 (MIC 8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albi
Evidence 3 Activity

Activity

MIC
Antibacterial
12-16.4 µg/mL

Target

B. subtilis

Source & Reference

dbAMP DRAMP

Other

oli ATCC 35150 or ATCC 10305 (MIC 8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albicans (MIC 2.1 ug/ml). Aslo histam
Evidence 4 Activity

Activity

MIC
Antibacterial
10 µg/mL

Target

L. monocytogenes ATCC 21633

Source & Reference

dbAMP DRAMP

Other

8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albicans (MIC 2.1 ug/ml). Aslo histamine release. Combined with activity data ana
Evidence 5 Activity

Activity

MIC
Antibacterial
2.1 µg/mL

Target

Candida albicans

Source & Reference

dbAMP DRAMP

Other

ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albicans (MIC 2.1 ug/ml). Aslo histamine release. Combined with activity data analyzed using recombinant OdC1 (see
Evidence 6 Activity

Activity

IC50
IC50 = 27.31 µM
Anticancer
27.31 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 7 Activity

Activity

IC50
IC50 = 41.21 µM
Anticancer
41.21 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 8 Activity

Activity

IC50
IC50 = 52.83 µM
Anticancer
52.83 µM

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 9 Activity

Activity

IC50
IC50 = 55.22 µM
Anticancer
55.22 µM

Target

Colon Cancer
LoVo
Colon

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 10 Activity

Activity

MIC
Antifungal
8.2-12 µg/mL

Target

Escherichia coli ATCC 35150 or ATCC 10305

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
active against E. coli ATCC 35150 or ATCC 10305 (MIC 8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogen
Evidence 11 Activity

Activity

MIC
Antifungal
4.1-10 µg/mL

Target

Staphylococcus aureus ATCC 25923

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

active against E. coli ATCC 35150 or ATCC 10305 (MIC 8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albi
Evidence 12 Activity

Activity

MIC
Antifungal
12-16.4 µg/mL

Target

B. subtilis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

oli ATCC 35150 or ATCC 10305 (MIC 8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albicans (MIC 2.1 ug/ml). Aslo histam
Evidence 13 Activity

Activity

MIC
Antifungal
10 µg/mL

Target

L. monocytogenes ATCC 21633

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albicans (MIC 2.1 ug/ml). Aslo histamine release. Combined with activity data ana
Evidence 14 Activity

Activity

MIC
Antifungal
2.1 µg/mL

Target

Candida albicans

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albicans (MIC 2.1 ug/ml). Aslo histamine release. Combined with activity data analyzed using recombinant OdC1 (see
Evidence 15 Activity

Activity

MIC
Antiparasitic
8.2-12 µg/mL

Target

Escherichia coli ATCC 35150 or ATCC 10305

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
active against E. coli ATCC 35150 or ATCC 10305 (MIC 8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogen
Evidence 16 Activity

Activity

MIC
Antiparasitic
4.1-10 µg/mL

Target

Staphylococcus aureus ATCC 25923

Source & Reference

DRAMP

Other

active against E. coli ATCC 35150 or ATCC 10305 (MIC 8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albi
Evidence 17 Activity

Activity

MIC
Antiparasitic
12-16.4 µg/mL

Target

B. subtilis

Source & Reference

DRAMP

Other

oli ATCC 35150 or ATCC 10305 (MIC 8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albicans (MIC 2.1 ug/ml). Aslo histam
Evidence 18 Activity

Activity

MIC
Antiparasitic
10 µg/mL

Target

L. monocytogenes ATCC 21633

Source & Reference

DRAMP

Other

8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albicans (MIC 2.1 ug/ml). Aslo histamine release. Combined with activity data ana
Evidence 19 Activity

Activity

MIC
Antiparasitic
2.1 µg/mL

Target

Candida albicans

Source & Reference

DRAMP

Other

ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albicans (MIC 2.1 ug/ml). Aslo histamine release. Combined with activity data analyzed using recombinant OdC1 (see
Evidence 20 Activity

Activity

MIC
Antiviral
8.2-12 µg/mL

Target

Escherichia coli ATCC 35150 or ATCC 10305

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets.
active against E. coli ATCC 35150 or ATCC 10305 (MIC 8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogen
Evidence 21 Activity

Activity

MIC
Antiviral
4.1-10 µg/mL

Target

Staphylococcus aureus ATCC 25923

Source & Reference

DRAMP

Other

active against E. coli ATCC 35150 or ATCC 10305 (MIC 8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albi
Evidence 22 Activity

Activity

MIC
Antiviral
12-16.4 µg/mL

Target

B. subtilis

Source & Reference

DRAMP

Other

oli ATCC 35150 or ATCC 10305 (MIC 8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albicans (MIC 2.1 ug/ml). Aslo histam
Evidence 23 Activity

Activity

MIC
Antiviral
10 µg/mL

Target

L. monocytogenes ATCC 21633

Source & Reference

DRAMP

Other

8.2-12 ug/ml), S. aureus ATCC 25923 (MIC 4.1-10 ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albicans (MIC 2.1 ug/ml). Aslo histamine release. Combined with activity data ana
Evidence 24 Activity

Activity

MIC
Antiviral
2.1 µg/mL

Target

Candida albicans

Source & Reference

DRAMP

Other

ug/ml), B. subtilis (MIC 12-16.4 ug/ml), L. monocytogenes ATCC 21633 (MIC 10 ug/ml), and C. albicans (MIC 2.1 ug/ml). Aslo histamine release. Combined with activity data analyzed using recombinant OdC1 (see
Evidence 25 Activity

Activity

0% Hemolysis
Toxicity
50 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 50 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Anti-infection peptidomics of amphibian skin. | Mol Cell Proteomics | 2007
Evidence 26 Activity

Activity

(2.9±1.5)% degranulation
Toxicity
50 µg/mL
Cytotoxic
(2.9±1.5)% degranulation | 50 | µg/mL | target cell: Human mast cells

Target

Human mast cells

Source & Reference

NA
DBAASP
Anti-infection peptidomics of amphibian skin. | Mol Cell Proteomics | 2007
Evidence 27 Activity

Activity

IC50
Toxicity
48.7 µM
Cytotoxic
IC50 | 48.7 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides. | Int J Mol Sci | 2021
Evidence 28 Activity

Activity

<10% Hemolysis
Toxicity
256 µM
Hemolytic Cytotoxic
<10% Hemolysis | 256 | µM | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides. | Int J Mol Sci | 2021
Evidence 29 Activity

Activity

Toxicity
Hemolytic
Hemolytic_activity: [Ref:17272268] No detectable hemolytic activity against rabbit red blood cells.

Target

erythrocytes

Source & Reference

NA
DRAMP
Mol Cell Proteomics. 2007 May 6(5):882-894.